Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
Rang in aandelen
#4334
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
Aandeelprijs
$3.87
Marktkapitalisatie
$3.57B
Verandering (1 dag)
-1.64%
Verandering (1 jaar)
9.08%
Land
CN
Handel Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Categorie
Healthcare
Winst voor Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Hubei Jumpcan Pharmaceutical Co., Ltd. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Hubei Jumpcan Pharmaceutical Co., Ltd. van 2001 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $309.05M | -24.26% |
| 2024 | $408.03M | -12.40% |
| 2023 | $465.78M | 28.11% |
| 2022 | $363.58M | 18.48% |
| 2021 | $306.87M | 35.13% |
| 2020 | $227.09M | -16.47% |
| 2019 | $271.87M | -5.40% |
| 2018 | $287.38M | 30.25% |
| 2017 | $220.64M | 40.80% |
| 2016 | $156.70M | 27.27% |
| 2015 | $123.13M | 26.13% |
| 2014 | $97.62M | 27.38% |
| 2013 | $76.64M | 66.50% |
| 2012 | $46.03M | 3,404.74% |
| 2011 | $1.31M | -0.73% |
| 2010 | $1.32M | 15.79% |
| 2009 | $1.14M | -13.96% |
| 2008 | $1.33M | -42.34% |
| 2007 | $2.30M | 28.76% |
| 2006 | $1.79M | 27.84% |
| 2005 | $1.40M | 13.48% |
| 2004 | $1.23M | -0.48% |
| 2003 | $1.24M | -50.58% |
| 2002 | $2.51M | -0.21% |
| 2001 | $2.51M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
